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Abstract
Premature infants are frequently exposed to aminoglycoside antibiotics. Novel urinary biomarkers may provide a non-
invasive means for the early identification of aminoglycoside-related proximal tubule renal toxicity, to enable adjustment of
treatment and identification of infants at risk of long-term renal impairment. In this proof-of-concept study, urine samples
were collected from 41 premature neonates (#32 weeks gestation) at least once per week, and daily during courses of
gentamicin, and for 3 days afterwards. Significant increases were observed in the three urinary biomarkers measured
(Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase-associated Lipocalin (NGAL), and N-acetyl-b-D-glucosaminidase
(NAG)) during treatment with multiple courses of gentamicin. When adjusted for potential confounders, the treatment
effect of gentamicin remained significant only for KIM-1 (mean difference from not treated, 1.35 ng/mg urinary creatinine;
95% CI 0.05–2.65). Our study shows that (a) it is possible to collect serial urine samples from premature neonates, and that
(b) proximal tubule specific urinary biomarkers can act as indicators of aminoglycoside-associated nephrotoxicity in this age
group. Further studies to investigate the clinical utility of novel urinary biomarkers in comparison to serum creatinine need
to be undertaken.
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Introduction
Acute Kidney Injury (AKI) is common in neonatal intensive
care units (estimated incidence 6–24%). [1] Neonates who have
AKI are at risk of later developing chronic renal disease and
hypertension. [2] Premature infants are commonly exposed to
potentially nephrotoxic medications (particularly aminoglycosides
(AGs) and non-steroidal anti-inflammatory drugs (NSAIDs)).
AG antibiotics (commonly gentamicin) are often used, in
combination with beta-lactams, for the treatment of neonatal
sepsis. There is an 8 to 30% incidence of nephrotoxicity (absolute
increase in serum creatinine level of 0.5 mg/dl) associated with
AG exposure in older age-groups, [3] but there is a paucity of data
quantifying AG-induced nephrotoxicity in neonates. [4] A study of
gentamicin toxicity in rats suggested that nephrotoxicity is greatest,
and occurs earlier, in the most immature animals. [5] Current
strategies for the prevention of AG-induced nephrotoxicity include
extended-interval dosing, and drug trough level mon‘itoring with
dose adjustment.
Accumulation of aminoglycosides within proximal tubule
epithelial cells (PTECs) in the renal cortex, following glomerular
filtration, by endocytosis via the multi-ligand receptor, megalin,
[6] is thought to be the key determining mechanism for the
development of toxicity. [7] Intracellular AG can result in
apoptosis or necrosis of PTECs by a variety of pathways
(mitochondrial dysfunction and the release of reactive oxygen
species) [8,9].
The traditional indicator of AKI is a rise in serum creatinine
concentration, but this has a delayed response with levels rising
significantly above baseline levels only when 25–50% of renal
function has been lost. [2] Furthermore, it is a marker of
glomerular filtration and not an indicator of proximal tubule
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function. Oliguria is, at best, a late sign of AKI, and may not be
present in many forms of AKI especially those related to toxins.
[10] Therefore, to identify infants early that are at increased risk of
renal impairment there is a need for biomarkers that reflect
different regions of the kidney that can be quantified earlier than
currently used indicators. This would, in turn, allow for treatment
adjustment and the avoidance of further injury.
A number of urinary biomarkers have been identified and have
been qualified for use in pre-clinical models that hold the potential
translational utility to identify drug-induced AKI in premature
neonates. For example, Kidney Injury Molecule-1 (KIM-1),
Neutrophil Gelatinase-associated Lipocalin (NGAL) and N-
acetyl-b-D-glucosaminidase (NAG) are urine-based indicators of
PTEC damage that are detectable earlier than currently used
clinical standards (serum creatinine and blood urea nitrogen).
Reports suggest that both NGAL and NAG hold translational
application to report tubular injury in both adults [11] and
children.[12–14] However, there is currently limited data inves-
tigating the potential utility of novel renal biomarkers to report
renal injury in the neonatal population. In particular, with respect
to KIM-1, prior to this study, there are no published data
investigating its use for the detection of nephrotoxicity associated
with AG therapy in neonates.
Therefore, the aims of this proof-of-concept study were to (a)
assess the feasibility of collecting serial urine samples from
premature neonates in the ICU setting; (b) measure a panel of
urinary biomarkers in the small volume of samples that could be
collected; and (c) determine whether elevations in these biomarkers
were associated with the use of nephrotoxic therapeutics in this
patient population and relate this to serum creatinine and
aminoglycoside levels. We hypothesized that due to the reported
utility of these biomarkers from preclinical data, elevations in all 3
biomarkers would be detected in the absence of serum creatinine
changes, and in confirmed cases of AKI, elevations in these
biomarkers will precede changes in serum creatinine concentra-
tion.
Methods
Patient Recruitment and Sample Collection
We recruited consecutive neonates with a gestational age less
than or equal to 32 weeks admitted to the Neonatal Intensive Care
Unit (NICU) at Liverpool Women’s Hospital, UK, between 1st
September 2009 and 24th December 2009. Neonates were
excluded if they had a known or suspected renal or chromosomal
abnormality, or if they were expected to die within 48 hours of
recruitment. The parents or guardians were approached between
days 4 to 7 of life of each eligible neonate and provided
information about the study. Informed consent was sought over
the next 24 hours. The study was conducted with the approval of
The Liverpool Paediatric Research Ethics Committee, University
of Liverpool, UK. Informed written consent was obtained from
carers or guardians on the behalf of the minors/children
participants involved in our study.
An initial urine sample was collected on day 5 to 8 of life, after
consent had been given. Further routine urine samples were
collected at weekly intervals for the duration of their stay at the
intensive care unit. Urine samples were collected as soon as
possible after beginning treatment with gentamicin (usually the
following morning). Samples were collected on a daily basis for the
duration of the antibiotic course, and until three days after the last
dose of gentamicin. Urine samples were collected using cotton
wool balls placed in the perineum inside the nappy. Urine from
non-faecal contaminated samples was transferred to a sterile
container and then centrifuged at 2000 g for 4 min. Supernatant
was then stored at 280uC.
Serum creatinine concentrations were measured (using the
compensated kinetic Jaffe reaction) as part of normal clinical care
for each neonate. No additional blood samples were taken, and no
extra tests ordered as part of the study.
Neonates who were treated with gentamicin received a dose of
4.5 mg/kg every 36 hours in accordance with local protocols.
Trough serum concentrations were measured just prior to the
second dose, and then every 3 to 4 days.
The local guideline for indomethacin recommended its use as
prophylaxis for intraventricular haemorrhage (IVH) in neonates
with a gestational age of ,28 weeks and/or birthweight ,1000 g:
3 doses of 100 mg/kg, given soon after birth, and then every
24 hours. Indomethacin was also recommended for treatment of
symptomatic patent ductus arteriosus (PDA) at a dose of 100 mg/
kg daily for 6 days.
Given that changes in hemodynamics can result in changes in
serum creatinine independent of any damage to the nephron, we
have defined AKI in this study as a serum creatinine concentration
.132.6micromol/l (1.5 mg/dl) which is slightly more than double
the median baseline serum creatinine value and/or oliguria (urine
output ,1 ml/kg/hour recorded at any point). This cut-off value
of serum creatinine for the definition of AKI in neonates has been
commonly used in previous studies [15]. Although newer proposed
criteria for the definition of AKI in neonates, such as the modified
Acute Kidney Injury Network (AKIN) criteria, may be more
sensitive [16], for the purposes of this study, we were most
interested in identifying those neonates with the most severe AKI.
Neonates were followed-up for the duration of their admission
on the unit, or until the end of the study period. Some neonates
were discharged home directly from the study unit, whereas others
were transferred to satellite neonatal units for further care before
discharge.
Determination of Urinary Biomarkers
Collected urine samples were thawed, mixed and centrifuged
(3000 rpm, 5 min). Biomarker measurements were performed on
the resulting supernatants. Urinary KIM-1 and NGAL measure-
ments were performed using microsphere-based Luminex tech-
nology, as previously described, using 25 ml of urine per biomarker
analysis, and analysed in duplicate. [17] Respective analytes were
quantified using a 13-point five parametric logarithmic standard
curve for each biomarker. The inter-and intra-assay variability was
less than 15% for all assays. Urinary NAG was determined
spectrophotometically according to the manufacturers’ protocols
(Roche Diagnostics), using 5 ml of urine per analysis, and analysed
in duplicate. The urinary levels of the respective analytes are
expressed as absolute (KIM-1 and NGAL) and enzymic activity
(NAG) values and normalized to urinary creatinine concentration.
Urinary creatinine (uCr) was determined spectrophotometically as
previously described, [18] using 25 ml of urine per analysis, and
analysed in duplicate. Investigators performed all analyte mea-
surements blindly and were unaware of the patients’ clinical
characteristics.
Statistical Analysis
We designed the study to combine weekly baseline measure-
ments with more frequent, daily, measurements in neonates on
gentamicin. This allowed us to determine baseline values taking
account of postmenstrual age and to assess changes in these
biomarkers. We hypothesised that we would see an increase in
each marker related to gentamicin administration due to PTEC
damage.
Renal Toxicity Biomakers in Neonates
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To assess the association between each biomarker and
gentamicin treatment, two aspects of the change in each
biomarker over the follow-up must first be accounted for. The
numerous biomarker values available for each neonate over the
follow-up are likely to be correlated. To account for this
correlation, generalised estimating equations (GEEs) were used
with exchangeable correlation (i.e. correlation between biomarker
measurements within neonates is constant). GEEs assume linear
relationships between each biomarker and time. However, the
change in the biomarker values over time is not linear (there are
peaks in biomarker values with gentamicin treatment which revert
to baseline following cessation of treatment). These changes over
time could be accounted for using polynomial equations (i.e. cubic
terms) within the GEEs. However, with an increasing number of
terms (i.e. knots) multi-colinearity is more likely, affecting the
estimate of the association between each of the biomarkers and
gentamicin treatment. Therefore, a better solution is to use
regression splines, which fit the best-fitting fractional polynominal.
The mfp program in Stata provides a framework for carrying
out both tasks simultaneously: selecting (fractional polynomial)
functions of the biomarker with time, and the GEE of the
biomarker with time. [19] Therefore we are able to account for the
change in each of the biomarkers over time and the correlation
between measurements. Accounting for both these aspects we are
then left to explore the association between treatment and each of
the biomarkers.
Postmenstrual age (weeks) was included in the models as it
might have an impact on overall differences in biomarkers over the
follow-up, and a term was included to assess if this impact changed
with time (e.g. impact of gestation diminished/increased over time
(later not reported)).
Actual mean difference and percentage difference in each
biomarker with gentamicin treatment, as well as baseline values for
each biomarker when not on treatment, were calculated. The
treatment effects are adjusted for confounders to assess if other
factors may explain the association between the biomarker and
treatment. Potential confounders were identified from the
following factors if they were significantly associated (p,0.05)
with each of the biomarkers: the episode of treatment received by
day of life, gestation (weeks), birth weight (kg), sex, Apgar score at
5 minutes, respiratory distress syndrome, received prophylactic
indomethacin in the first week of life, received indomethacin (yes
or no, for each day), received furosemide (yes or no, for each day),
serum creatinine concentration by day of life, and occurrence of a
co-morbidity (yes or no, for each day). Co-morbidities were any of
the following: sepsis (blood culture positive), necrotising enteroco-
litis, cardiopulmonary resuscitation, need for oscillator/high flow
oxygen ventilation/nitric oxide, need for inotropes, or surgery.
Results
Overview of Urine Collection and the Incidence of
Gentamicin Therapy
A total of 41 neonates were recruited to the study. Summary
characteristics are presented in Table 1. A median of 4 urine
samples (Inter-quartile Range (IQR) 2–12) were collected for each
neonate. The majority of urine samples measured between 1 and
5 ml, with the smallest amount being 200 ml in a few patients, but
this was still adequate to perform all the assays. The median length
of follow-up per neonate was 30 days (IQR 14–48). The first urine
sample was taken at a median of day 7 (IQR 6–7).
40 of the 41 patients (97.6%) received treatment with
gentamicin during the first week of life. Twenty-one (51.2%) went
on to have 2 or more treatment courses of gentamicin during the
T
a
b
le
1
.
B
as
e
lin
e
ch
ar
ac
te
ri
st
ic
s
an
d
cl
in
ic
al
si
g
n
s
o
f
n
e
o
n
at
e
s
tr
e
at
e
d
w
it
h
g
e
n
ta
m
ic
in
.
N
u
m
b
e
r
M
e
a
n
b
io
m
a
rk
e
r
v
a
lu
e
G
e
st
a
ti
o
n
(w
e
e
k
s)
N
u
m
b
e
r
M
e
a
n
B
ir
th
w
e
ig
h
t
(k
g
)
M
a
le
s
R
e
sp
ir
a
to
ry
D
is
tr
e
ss
In
d
o
m
e
th
a
ci
n
P
ro
p
h
y
la
x
is
A
cu
te
K
id
n
e
y
In
ju
ry
U
ri
n
a
ry
K
IM
-1
(n
g
/m
g
u
C
r)
U
ri
n
a
ry
N
A
G
(I
U
/m
g
u
C
r)
U
ri
n
a
ry
N
G
A
L
(n
g
/m
g
u
C
r)
S
e
ru
m
C
re
a
ti
n
in
e
(m
ic
ro
m
o
l/
l)
,
2
6
6
0
.7
5
8
3
6
6
4
3
.6
4
0
.2
8
1
0
4
6
.7
2
9
3
.3
7
2
6
to
,
2
8
9
0
.8
9
3
6
9
8
1
2
.8
5
0
.1
4
6
3
2
.6
8
5
6
.5
1
2
8
to
,
3
0
1
1
1
.1
0
6
6
1
0
2
0
2
.6
7
0
.1
8
5
3
8
.4
9
5
6
.1
2
3
0
to
3
2
1
5
1
.4
9
9
1
0
1
1
0
0
0
.7
2
0
.0
5
8
2
.7
6
5
4
.1
9
P
at
ie
n
ts
ar
e
su
b
d
iv
id
e
d
ac
co
rd
in
g
to
g
e
st
at
io
n
al
ag
e
.
M
e
an
b
io
m
ar
ke
r
va
lu
e
s
p
re
se
n
te
d
in
cl
u
d
e
sa
m
p
le
s
co
lle
ct
e
d
b
o
th
o
n
an
d
o
ff
g
e
n
ta
m
ic
in
tr
e
at
m
e
n
t
o
ve
r
th
e
w
h
o
le
ti
m
e
co
u
rs
e
o
f
in
cl
u
si
o
n
in
th
e
st
u
d
y.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
4
3
8
0
9
.t
0
0
1
Renal Toxicity Biomakers in Neonates
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e43809
follow-up period. The median number of days of gentamicin
treatment for any particular neonate was 5 (IQR 1–8) and median
episodes of treatment was 2 (IQR 1–2). Only one participant did
not receive any gentamicin. 8 patients were discharged home, 16
were transferred to other neonatal units, 2 were withdrawn from
the study by their parents, 3 died, and 12 remained on our NICU
at the end of the study follow-up.
Evaluation of Novel Urinary Biomarkers in Cases of
Confirmed AKI
Five patients developed AKI during the course of the study as
defined by a sCr concentration .132.6 micromol/l (1.5 mg/dl)
and/or oliguria (urine output ,1 ml/kg/hour recorded at any
point). In this patient group, we investigated the hypothesis that
it was feasible to measure a panel of urinary biomarkers, and
that in cases when serum creatinine was elevated, the urinary
concentration of each of the novel mechanism-based biomarkers
would also be increased. During episodes of AKI patients had
significantly increased mean values of KIM-1 (mean difference
5.84 ng/mg uCr; 95% CI 3.77, 7.92), NGAL (mean difference
2031.7 ng/mg uCr; 95% CI 1351.4, 2711.9), and NAG (mean
difference 0.53 IU/mg uCr; 95% CI 0.39, 0.68) compared to
those without AKI. Representative figures are given for three
infants (Fig. 1).
Assessment of the Impact of Gentamicin Treatment on
the Concentration of Urinary Biomarkers
After determining that measuring each of these urinary
biomarkers was feasible in this patient group in the ICU setting
using the method that we employed for urine collection, and that
their concentration increased in the presence of confirmed AKI,
we next explored the relationship between the urinary biomarker
concentration and incidence of gentamicin treatment. Figure 2
illustrates representative data from three patients treated with
multiple courses of gentamicin. Multiple treatment courses (21/41
patients), in particular, were associated with transient increases in
KIM-1, NGAL and NAG. No elevation in any of the biomarkers
investigated was seen in the one patient that was not exposed to
gentamicin. Interestingly, in the patients without confirmed AKI
that were treated with multiple course of gentamicin (16/21), the
urinary concentration increase following gentamicin treatment
was observed in the absence of a change in serum creatinine
concentration. An analysis of the association between gentamicin
treatment and biomarker values is presented in table 2 for all
patients recruited to the study.
Determination of Baseline Urinary Biomarker Values and
the Effect of Gentamicin Treatment
After observing the association between drug treatment and
biomarker elevations, we next sought to establish baseline values
for each patient to assess the impact and significance of changes in
biomarker values. The mean baseline values, in the absence of any
gentamicin treatment, were 1.91 ng/mg uCr (95% CI 1.07, 2.76)
for KIM-1, 0.13 IU/mg uCr (0.07, 0.19) for NAG, 425.4 ng/mg
uCr (162.6, 688.3) for NGAL, and 62.39 mmol/l (53.1, 71.69) for
creatinine. There was a significant difference observed in the value
of all three urinary biomarkers between those treated and those
not treated with gentamicin on any given day (table 2). These
figures take account of the variability and correlation in the
biomarker measurements within neonates over the follow-up
period, as described in the statistical analysis section. Between
courses of gentamicin, each biomarker returned to a value not
significantly different from the value in those patients not receiving
gentamicin.
The factors associated with KIM-1 in the univariate analysis,
and therefore treated as potential confounders in the multivariate
analysis, included gestation, prophylactic indomethacin, co-mor-
bidities and serum creatinine (sCr). The same factors were also
associated with NGAL and NAG in the univariate analysis, with
the addition of gentamicin episode number for NAG. The
association between gentamicin treatment and KIM-1 elevations
remained after adjusting for potential confounders (mean differ-
ence 1.35 ng/mg uCr; 95% CI 0.05, 2.65), but not for NAG and
NGAL (table 2).
Evaluation of the Impact of other Medications on Urinary
Biomarker Elevations
The NSAID, indomethacin, is commonly prescribed to
neonates in an ICU setting, the use of which has been reported
to be associated with renal toxicity, although this would not
selectively affect the proximal tubule. Indomethacin treatment had
no significant effect on the urinary concentration of KIM-1
(21.31 ng/mg uCr; 95% CI 26.06, 3.44) and NGAL
(2543.15 ng/mg uCr; 95% CI 22119.88, 1033.58), or the
urinary enzymatic activity of NAG (20.09 IU/mg uCr; 95% CI
20.42, 0.24).
Discussion
Animal models of paediatric gentamicin toxicity have suggested
that immature rats (aged 10 days) developed gentamicin-induced
nephrotoxicity earlier, and to a greater extent, than more mature
rats. [5] The level of renal maturity in 10-day old rats is similar to
that found prenatally in humans [5], suggesting that preterm
neonates may be at increased risk of gentamicin-induced
nephrotoxicity compared to older children. Thus, it is important
to develop methods to investigate renal injury caused by drugs in
this vulnerable patient group. Our proof-of-concept investigation
shows that it is feasible to collect serial urine samples, and despite
the fact that only small volumes of urine were collected, it was
possible to measure a panel of urinary biomarkers in a
reproducible manner.
We hypothesized that urinary concentrations of the novel
urinary biomarkers, KIM-1, NGAL and NAG would be elevated
during AG treatment in the absence of, or before, changes in
serum creatinine. Within this study, we found significant elevations
in three urinary biomarkers (KIM-1, NGAL and NAG) in
premature neonates during courses of treatment with gentamicin,
which occurred in the absence of a significant increase in sCr.
Once gentamicin was withdrawn, the biomarkers returned to
baseline values, similar to that found prior to AG treatment in the
same infant. Those neonates who developed AKI had higher
mean values of all 3 urinary biomarkers. Adjustment for potential
confounders showed that the increase in biomarker value
remained significant only for KIM-1, but the confidence intervals
for NGAL and NAG bordered on significance which may reflect
our small sample size. It is important to note that this investigation
represents the first determination of the urinary abundance of
KIM-1 following drug treatment in pre-term neonates. Our
findings clearly need independent replication, but it is also
important to ensure that future studies are adequately powered
to determine whether one of the biomarkers has superior
predictive ability compared to the others.
NGAL has previously been evaluated in neonates: in a study of
20 patients, although there was marked variability in urinary
NGAL levels, it had a sensitivity of 31% for predicting oliguria,
Renal Toxicity Biomakers in Neonates
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and a specificity of 90%. [20] Two more recent reports have
provided reference values for urinary NGAL in premature
neonates. [21,22] A direct comparison with the values reported
in our study, however, is not possible as different measurement
methods have been used, and our values are corrected for urinary
Cr whereas the other studies have reported only absolute values.
Urinary NGAL serves as a biomarker of sepsis-induced kidney
injury [23]; this is consistent with our finding that co-morbidities,
including sepsis, were a significant confounder of the gentamicin-
associated increase in urinary NGAL. This may indicate that
changes in NGAL values are more closely associated with the
septic state than with exposure to gentamicin, which would be
consistent with its role in the regulation of inflammation. [24,25]
As with NGAL, the potential utility of NAG has previously been
studied in neonates receiving AGs. Consistent with our findings,
NAG increases during treatment with AGs and returned to
baseline levels following drug withdrawal. [26] One recent study,
however, found no significant difference in urinary NAG
concentrations between neonatal infants treated with gentamicin
for 10 days, and a control group. [27] NAG has also been shown
to increase following perinatal asphyxia and the related renal
ischaemic damage. [28].
There has been recent interest in measuring panels of urinary
biomarkers in paediatric populations. In children attending an
emergency centre, urinary NGAL and KIM-1 both demonstrated
good accuracy in predicting patients with a greater than 50%
reduction in estimated creatinine clearance. [29] These same two
biomarkers were also useful as markers of worsening differential
renal function in congenital obstructive nephropathy. [30] In
preterm neonates, measurement of a panel of urinary biomarkers
(which included NGAL and KIM-1) has recently been reported.
[31] They found that values of these biomarkers were highest in
the most premature. Our findings are in agreement with this, our
baseline values were broadly similar, and we have accounted for
gestational age in our analysis. The same group has also reported
that urine biomarkers (again including NGAL and KIM-1) had
good predictive value for AKI and mortality in very low birth
weight infants. [32].
This study was designed to serve as a foundation for evaluation
in future studies and demonstrates the feasibility of measuring a
panel of biomarkers in urine samples from premature neonates.
Figure 1. Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin with a change in serum creatinine
concentration (AKI). Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL
(green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; mmol/L) for three infants treated with gentamicin (A–C). Gentamicin
treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.
doi:10.1371/journal.pone.0043809.g001
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Our combination of regular weekly baseline measurements with
an increased frequency of sampling during gentamicin treatment
enabled us to assess changes in the measured biomarkers during
these courses. Despite the relatively small number of neonates who
participated in this study, we have been able to show significant
changes in our biomarkers related to courses of gentamicin
exposure via a longitudinal analysis. It is important to note that the
development of a rapid urine dipstick test for KIM-1 [33] and
bedside analysis for NGAL [34] suggests that these biomarkers
could be measured in real time, increasing their potential clinical
utility. In our study, we also noted that biomarker values decreased
with increasing postmenstrual age. This suggests a differential
sensitivity to renal insults with postmenstrual age, a concept
reported pre-clinically [5] and is similar to our recent report of
baseline levels of hepatic transaminases in preterm neonates. [35]
However, this needs to be confirmed in a larger dataset.
Despite the novel findings of this current investigation, several
limitations exist. First, the sample size was small. However, this
was a proof-of-concept study, and the longitudinal analysis
employed here provides a powerful insight into the dynamics
and responses to drug treatment of each of the biomarkers
investigated in the clinical setting. Due to the small number of
confirmed cases of AKI, the relative sensitivity of each biomarker
at reporting renal injury compared to currently used clinical
standards could not be assessed with statistical confidence.
However, the data provided within this investigation supports
the feasibility of such future studies. Second, a number of neonates
had only short stays in the NICU, often being transferred to
regional units for continuation of their care closer to home. This
meant that for some the period of follow-up following their
baseline sample was relatively short. Further follow-up studies are
planned to determine whether or not multiple courses of
gentamicin exposure in neonates have a lasting effect on renal
function. Third, 40 of our 41 participants received gentamicin in
the first week of life, and a small number were on gentamicin when
the first urine sample was collected. This means we do not have
true, pre-gentamicin, baseline measurements of our biomarkers in
all patients. Finally, although we have determined urinary
biomarker changes associated with gentamicin treatment within
this current investigation, we have not correlated this with clinical
outcome or clinical decision making. It is important that future
studies are appropriately designed so that guidance can be given
Figure 2. Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin without a change in serum
creatinine concentration. Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL
(green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; mmol/L) for three infants treated with gentamicin (A–C). Gentamicin
treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.
doi:10.1371/journal.pone.0043809.g002
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on what clinical decisions (i.e. drug withdrawal or dose modifica-
tion) need to be made in clinical settings when novel biomarkers
are found to be elevated above baseline.
In conclusion, we have shown that it is possible to collect
adequate volumes of serial urine samples to measure a panel of
novel urinary biomarkers in premature neonates exposed to
gentamicin. The application of the assays, the biomarkers
investigated in this patient population in the ICU setting and the
statistical analysis used, represent novel outcomes from this
research. This proof-of-concept study will inform the design of
further qualification studies of urinary biomarkers in larger
neonatal cohorts which will include assessment of their relative
sensitivity to predict AKI, compared to current clinical indicators.
Furthermore, such studies should be carefully designed to answer
the important questions as to whether changes in clinical
management (stopping the drug or altering dosage) lead to better
patient outcomes both in terms of treatment of their underlying
infection, and also whether further more serious kidney injury is
averted.
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